EP4017859A4 - Alkylquarternäre ammoniumtryptamine und ihre therapeutischen verwendungen - Google Patents

Alkylquarternäre ammoniumtryptamine und ihre therapeutischen verwendungen Download PDF

Info

Publication number
EP4017859A4
EP4017859A4 EP20858480.5A EP20858480A EP4017859A4 EP 4017859 A4 EP4017859 A4 EP 4017859A4 EP 20858480 A EP20858480 A EP 20858480A EP 4017859 A4 EP4017859 A4 EP 4017859A4
Authority
EP
European Patent Office
Prior art keywords
tryptamines
therapeutic uses
quarternary ammonium
alkyl quarternary
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20858480.5A
Other languages
English (en)
French (fr)
Other versions
EP4017859A1 (de
Inventor
Andrew R. Chadeayne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Caamtech Inc
Original Assignee
Caamtech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caamtech Inc filed Critical Caamtech Inc
Publication of EP4017859A1 publication Critical patent/EP4017859A1/de
Publication of EP4017859A4 publication Critical patent/EP4017859A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
EP20858480.5A 2019-08-25 2020-08-25 Alkylquarternäre ammoniumtryptamine und ihre therapeutischen verwendungen Pending EP4017859A4 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962891388P 2019-08-25 2019-08-25
US202063007653P 2020-04-09 2020-04-09
US202063053976P 2020-07-20 2020-07-20
PCT/US2020/047791 WO2021041407A1 (en) 2019-08-25 2020-08-25 Alkyl quarternary ammonium tryptamines and their therapeutic uses

Publications (2)

Publication Number Publication Date
EP4017859A1 EP4017859A1 (de) 2022-06-29
EP4017859A4 true EP4017859A4 (de) 2023-08-23

Family

ID=74684268

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20858480.5A Pending EP4017859A4 (de) 2019-08-25 2020-08-25 Alkylquarternäre ammoniumtryptamine und ihre therapeutischen verwendungen

Country Status (4)

Country Link
EP (1) EP4017859A4 (de)
AU (1) AU2020337903A1 (de)
CA (1) CA3149602A1 (de)
WO (1) WO2021041407A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
US11701348B1 (en) 2016-07-23 2023-07-18 Turtle Bear Holdings, Llc Psilocybin compositions
US20210069170A1 (en) 2016-07-23 2021-03-11 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
US11660305B2 (en) 2019-11-19 2023-05-30 Turtle Bear Holdings, Llc Tryptamine compositions for enhancing neurite outgrowth
AU2021237640B2 (en) * 2020-03-19 2024-01-04 Caamtech, Inc. Crystalline psilacetin derivatives
US11858896B2 (en) 2020-05-04 2024-01-02 Caamtech, Inc. Crystalline dimethyl tryptamine analogues
AU2021276656A1 (en) 2020-05-19 2022-11-24 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
WO2021250434A1 (en) 2020-06-12 2021-12-16 Beckley Psytech Limited Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
AU2022328217A1 (en) 2021-08-12 2024-03-14 Kuleon Llc Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same
WO2023023298A1 (en) * 2021-08-20 2023-02-23 Psilosterics, Llc Hallucinogenic and non-hallucinogenic compounds and methods of making and using the same
CA3235016A1 (en) * 2021-10-15 2023-04-20 Andrew R. Chadeayne Crystalline tryptamine compounds
WO2023173227A1 (en) * 2022-03-18 2023-09-21 Enveric Biosciences Canada Inc. C4-substituted tryptamine derivatives and methods of using
WO2023173196A1 (en) 2022-03-18 2023-09-21 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
WO2023205768A2 (en) * 2022-04-21 2023-10-26 Caamtech, Inc. Crystalline quaternary salts of 4-substituted tryptamines
WO2023250465A2 (en) * 2022-06-24 2023-12-28 Caamtech, Inc. Tryptamine derivatives
WO2024026291A1 (en) * 2022-07-25 2024-02-01 Caamtech, Inc. Methyl substituted quaternary tryptamine derivatives
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306181B1 (en) * 1998-09-21 2001-10-23 L'oreal Cationic 4-hydroxyindoles, their use for the oxidation dyeing of keratinous fibers, dyeing compositions, and methods of dyeing
US20160374964A1 (en) * 2014-07-03 2016-12-29 Wisconsin Alumni Research Foundation Antimicrobial compounds, compositions and methods of use thereof
US20180221396A1 (en) * 2017-02-09 2018-08-09 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
US20190142851A1 (en) * 2017-11-16 2019-05-16 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306181B1 (en) * 1998-09-21 2001-10-23 L'oreal Cationic 4-hydroxyindoles, their use for the oxidation dyeing of keratinous fibers, dyeing compositions, and methods of dyeing
US20160374964A1 (en) * 2014-07-03 2016-12-29 Wisconsin Alumni Research Foundation Antimicrobial compounds, compositions and methods of use thereof
US20180221396A1 (en) * 2017-02-09 2018-08-09 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
US20190142851A1 (en) * 2017-11-16 2019-05-16 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
E.K. OLSEN ET. AL.: "Marine AChE inhibitors isolated from Geodia barretti: Natural compounds and their synthetic analogs.", ORGANIC AND BIOMOLECULAR CHEMISTRY, vol. 14, 1 May 2016 (2016-05-01), pages 1629 - 1640, XP093061966, DOI: 10.1039/c5ob02416a *
H. WIELAND ET. AL.: "Die Konstitution von Bufotenin und Bufotenidin .Über Kröten Giftstoffe. VII.", JUSTUS LIEBIGS ANNALEN DER CHEMIE, vol. 513, 1 January 1934 (1934-01-01), pages 1 - 25, XP093062000, DOI: 10.1002/jlac.19345130102 *
L. SERVILLO ET. AL.: "N-Methylated Tryptamine Dervatives in Citrus Genus Plants. Identification of N,N,N-triethyl-Tryptamine in Bergamot", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 60, no. 37, 19 September 2012 (2012-09-19), pages 9512 - 9518, XP055802747, DOI: 10.1021/jf302767e *
R.B. BARLOW ET. AL.: "Actions of some analogues of 5-hydroxy-tryptamine on the isolated rat uterus and the rat fundus strip preparations.", BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, vol. 14, 1 January 1959 (1959-01-01), pages 265 - 266, XP093061989, DOI: 10.1111/j.1476-5381.1959.tb01397.x *

Also Published As

Publication number Publication date
AU2020337903A1 (en) 2022-03-31
EP4017859A1 (de) 2022-06-29
CA3149602A1 (en) 2021-03-04
WO2021041407A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
EP4017859A4 (de) Alkylquarternäre ammoniumtryptamine und ihre therapeutischen verwendungen
EP3574018A4 (de) Gegen tumor gerichtete konjugate und verfahren zur verwendung davon
EP3634430A4 (de) Multibiotika und verwendungsverfahren dafür
EP3873530A4 (de) Therapeutische verfahren
EP3768258A4 (de) Kombinationstherapie
EP3837240A4 (de) Substituierte indole und verfahren zur verwendung davon
EP3803771A4 (de) Züchterübergreifende studie und feldfokussierung
EP3697764A4 (de) Glutaminase-hemmertherapie
EP3740576A4 (de) Therapeutische zusammensetzungen und verfahren zur herstellung und verwendung davon
EP3675991A4 (de) Generator für freie radikale und verwendungsverfahren
EP3737391A4 (de) Gegen cd99-exprimierenden krebs gerichtete zusammensetzungen und verfahren
EP3737400A4 (de) Gegen clec12a-exprimierende karzinome gerichtete zusammensetzungen und verfahren
EP3836971A4 (de) Konjugate und verfahren zur verwendung davon
EP3784326A4 (de) Vorrichtung zur aurikularen stimulation des nervenfelds
EP3873478A4 (de) Verfahren zur verbesserung einer immunbasierten therapie
EP3893874A4 (de) Crenolanibkombinationstherapie
EP4037715A4 (de) Proteinmakromolekülkonjugate und verfahren zu ihrer verwendung
EP3790889A4 (de) Therapeutische und diagnostische zusammensetzungen, die auf toll-like-rezeptoren abzielen, und verfahren dafür
EP3638270A4 (de) Zusammensetzungen und verfahren zur verbesserung einer hyperthermietherapie
IL304245A (en) Phospholipid-flaveglin conjugates and methods of using them for targeted cancer treatment
EP3969460A4 (de) Ascarosidderivate und verfahren zur verwendung
TWI799840B (zh) 靶向介白素-34之化合物及方法
EP3601962A4 (de) Akustische durchflussmessgeräte und verfahren zur verwendung davon
EP3615502A4 (de) Therapeutische verbindungen und verfahren
EP3576834A4 (de) Implantierbarer nervenwandler

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220304

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20230726

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4045 20060101ALI20230720BHEP

Ipc: C07D 209/16 20060101ALI20230720BHEP

Ipc: C07D 487/04 20060101AFI20230720BHEP